admin – Page 4157 – Get News Story

Hereditary Angioedema Market Expected to rise, 2034 | KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, expected to drive market

“Hereditary Angioedema Market 2034”

The Hereditary Angioedema market growth is driven by factors like increase in the prevalence of Hereditary Angioedema, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Hereditary Angioedema market report also offers comprehensive insights into the Hereditary Angioedema market size, share, Hereditary Angioedema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hereditary Angioedema market size growth forward.

Some of the key highlights from the Hereditary Angioedema Market Insights Report:

Several key pharmaceutical companies, including KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, and others, are developing novel products to improve the Hereditary Angioedema treatment outlook.
In February 2024, BioCryst launched ORLADEYO (berotralstat) in Italy.
In January 2024, Ionis announced positive topline results from the Phase III OASIS-HAE study, which evaluated the investigational drug donidalorsen for hereditary angioedema (HAE). Following these promising findings, Ionis is preparing to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
In December 2023, CSL Behring reported that the FDA had accepted a Biologics License Application (BLA) for garadacimab (CSL312), proposed as a monthly prophylactic treatment for HAE.
As per DelveInsight analysis, the Hereditary Angioedema market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Hereditary Angioedema Market Landscape

Hereditary Angioedema Overview

Hereditary Angioedema (HAE) is a rare genetic condition characterized by vasogenic edema due to a deficiency of functional C1 inhibitor (C1-INH). This deficiency leads to recurrent episodes of localized subcutaneous or mucosal swelling, commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.

Symptoms include sudden swelling around the eyes, face, and extremities, abdominal pain caused by bowel edema, and laryngeal edema, which can result in hoarseness, breathing difficulties, and potentially fatal outcomes. Early diagnosis and treatment are essential to improving quality of life and preventing life-threatening events, as even a single laryngeal edema episode can be fatal.

Diagnosis involves evaluating clinical symptoms, family history, and laboratory tests. Recurrent abdominal pain or edema without urticaria, especially in individuals with a family history of HAE, should raise suspicion of the condition.

Do you know the treatment paradigms for different countries? Download our Hereditary Angioedema Market Sample Report

Hereditary Angioedema Epidemiology Insights

In 2021, the United States had the highest number of diagnosed prevalent cases of Hereditary Angioedema (HAE) among the 7MM+China, with 7,614 cases. Within Europe, the UK reported the largest diagnosed prevalent population, with approximately 1,348 cases, followed by Germany with 1,266 cases. In contrast, Spain and Italy had the lowest diagnosed prevalent populations, each with approximately 942 cases.

Hereditary Angioedema Epidemiology Segmentation

DelveInsight’s Hereditary Angioedema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hereditary Angioedema historical patient pools and forecasted Hereditary Angioedema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hereditary Angioedema Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

Hereditary Angioedema Prevalence
Age-Specific Hereditary Angioedema Prevalence
Gender-Specific Hereditary Angioedema Prevalence
Diagnosed and Treatable Cases of Hereditary Angioedema

Visit for more @ Hereditary Angioedema Epidemiological Insights

Hereditary Angioedema Market Insights:

In 2021, the total market size for Hereditary Angioedema (HAE) in the 7MM+China was approximately USD 2,152 million, with steady growth anticipated through 2032 at a moderate CAGR. The United States dominated the market, accounting for around USD 1,769 million in 2021, and is projected to see continued growth over the forecast period (2022–2032). The combined market size of the EU4 and the UK was estimated at USD 347 million in 2021 and is expected to increase further by 2032.

Hereditary Angioedema Market Outlook

Although there is no cure for Hereditary Angioedema (HAE), various approaches can help prevent or manage swelling attacks. Several HAE-specific treatments are available, including attenuated androgens; however, access to some medications may be limited by regional availability, regulatory approvals, or cost. Other less-established options, such as antifibrinolytics and fresh frozen plasma, may also play a role in certain cases.

The HAE treatment landscape is broadly divided into two strategies: on-demand therapies, used to quickly alleviate and resolve angioedema symptoms during an attack, and prophylactic treatments. Long-term prophylaxis reduces the overall disease burden, while short-term or periprocedural prophylaxis is used before known triggers to prevent attacks.

Hereditary Angioedema Marketed Drugs

FIRAZYR: Shire/Takeda
ORLADEYO (berotralstat): BioCryst Ireland Limited

Hereditary Angioedema Emerging Drugs

Sebetralstat (KVD900): KalVista Pharmaceuticals
Garadacimab (CSL312): CSL Behring

Hereditary Angioedema Key Companies

KalVista Pharmaceuticals
Intellia Therapeutics
BioMarin Pharmaceutical

For more information, visit Hereditary Angioedema Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Hereditary Angioedema Market Report:

11 Years Forecast
7MM Coverage
Descriptive overview of Hereditary Angioedema, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Hereditary Angioedema epidemiology in the 7MM
Hereditary Angioedema marketed and emerging therapies
Hereditary Angioedema companies
Hereditary Angioedema market drivers and barriers

Table of Contents:

1 Hereditary Angioedema Market Key Comprehensive Insights

2 Hereditary Angioedema Market Report Introduction

3 Competitive Intelligence Analysis for Hereditary Angioedema

4 Hereditary Angioedema Market Analysis Overview at a Glance

5 Executive Summary of Hereditary Angioedema

6 Hereditary Angioedema Epidemiology and Market Methodology

7 Hereditary Angioedema Epidemiology and Patient Population

8 Hereditary Angioedema Patient Journey

9 Hereditary Angioedema Treatment Algorithm, Hereditary Angioedema Current Treatment, and Medical Practices

10 Key Endpoints in Hereditary Angioedema Clinical Trials

11 Hereditary Angioedema Marketed Therapies

12 Hereditary Angioedema Emerging Therapies

13 Hereditary Angioedema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Hereditary Angioedema

16 Hereditary Angioedema Market Key Opinion Leaders Reviews

18 Hereditary Angioedema Market Drivers

19 Hereditary Angioedema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Hereditary Angioedema Epidemiology 2034

DelveInsight’s “Hereditary Angioedema – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Hereditary Angioedema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Hereditary Angioedema Pipeline 2024

“Hereditary Angioedema Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hereditary Angioedema market. A detailed picture of the Hereditary Angioedema pipeline landscape is provided, which includes the disease overview and Hereditary Angioedema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Angioedema Market Expected to rise, 2034 | KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, expected to drive market

Hypertrophic Cardiomyopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

“Hypertrophic Cardiomyopathy Treatment Market”

Hypertrophic Cardiomyopathy Companies are Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others.

(Albany, UJSA) DelveInsight’s “Hypertrophic Cardiomyopathy Market Insights, Epidemiology and Market Forecast 2034” report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Hypertrophic Cardiomyopathy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Hypertrophic Cardiomyopathy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

Unlock detailed insights into the Hypertrophic Cardiomyopathy Market by downloading the comprehensive report from DelveInsight @ Hypertrophic Cardiomyopathy Treatment Market Size

Key Takeaways from the Hypertrophic Cardiomyopathy Market Report

The Hypertrophic Cardiomyopathy market size was valued ~USD 646 million in 2023 and is anticipated to grow with a significant CAGR of 20% during the study period (2020-2034)
In December 2024, Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease, has announced promising early results from the first cohort of patients in the MyPEAK-1 clinical trial of TN-201 gene therapy. TN-201 is being developed as a potential treatment for MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by inadequate levels of myosin-binding protein C (MyBP-C).
In September 2024, Edgewise Therapeutics reported promising top-line results from two clinical trials evaluating EDG-7500 as a potential treatment for obstructive hypertrophic cardiomyopathy (HCM). The findings include data from a Phase I trial in healthy participants and the single-dose arm of the Phase II CIRRUS-HCM trial. EDG-7500, an oral and selective modulator, is specifically designed to target cardiac relaxation challenges associated with HCM.
In April 2024, Imbria Pharmaceuticals, Inc., a clinical-stage cardiometabolic company focused on developing innovative therapies to enhance patient symptoms and functional capacity by improving cellular energetics, announced that findings from the Phase 2 IMPROVE-HCM clinical trial investigating ninerafaxstat in patients with symptomatic nHCM were unveiled during a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).
As per DelveInsight’s assessments, males are more affected by HCM than females. Also, the cases are projected to increase by 2034 in the United States.
As per assessments by DelveInsight analysts, there were nearly 2,887 diagnosed prevalent cases of Obstructive HCM (HOCM), and 1,443 diagnosed prevalent cases of Non-obstructive HCM (HNCM) in 2023 in Japan.
In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of HCM in the 7MM was 246,272 in 2023. The highest diagnosed prevalent cases of HCM were accounted by the US for 48% in 2022 which were approximately of the 7MM. These cases are expected to increase during the forecast period (2023–2034).
Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others

Gain a competitive edge in the Hypertrophic Cardiomyopathy Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Hypertrophic Cardiomyopathy Treatment Drugs

Hypertrophic Cardiomyopathy Epidemiology Segmentation in the 7MM

Total Prevalent Cases
Diagnosed Prevalent Cases
Gender-specific Diagnosed Prevalent Cases
Type-specific Diagnosed Prevalent Cases
Total Treated Cases

Hypertrophic Cardiomyopathy Market Insights

Current pharmacological strategies for hypertrophic cardiomyopathy (HCM) focus on symptom management, particularly for obstructive HCM. Treatment primarily targets left ventricular outflow tract (LVOT) obstruction, using β-adrenergic antagonists, calcium channel blockers, and antiarrhythmic drugs. “CAMZYOS (Mavacamten) is the first and only cardiac myosin inhibitor approved by the US FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.”

Discover key developments and opportunities in the Hypertrophic Cardiomyopathy Market. Click here to learn more from DelveInsight’s latest report @ Hypertrophic Cardiomyopathy Market Size

Hypertrophic Cardiomyopathy Marketed Drugs

Mavacamten: Bristol Myers Squibb

Mavacamten is an investigational, novel, oral, allosteric modulator of cardiac myosin; mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation, resulting in hypercontractility, left ventricular hypertrophy, and reduced compliance.

Hypertrophic Cardiomyopathy Emerging Drugs

Aficamten (CK-274): Cytokinetics

Aficamten, or CK-274, is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations for the potential treatment of hypertrophic cardiomyopathies (hypertrophic cardiomyopathy).

MYK-224: Bristol Myers Squibb

MYK-224 is a small molecule drug that is being developed by MyoKardia, a subsidiary of Bristol-Myers Squibb, to treat diastolic heart failure (HFpEF) and obstructive hypertrophic cardiomyopathy. It is taken orally and targets the heart’s cardiac myosin motor protein to normalize filling and contractility.

Hypertrophic Cardiomyopathy Market Outlook

Cardiomyopathy is a term that refers to abnormalities of heart muscle contractility, covering a heterogeneous range of etiologies. Hypertrophic cardiomyopathy is characterized by left ventricular hypertrophy and hypercontractility. It is almost always caused by mutations of genes encoding sarcomeric proteins. Current pharmacological treatment strategies of Hypertrophic cardiomyopathy are mainly centered on managing the symptoms and minimizing disease progression. However, it is important to keep in mind that these strategies are not disease-specific since they target the neurohormonal system and excitation–contraction coupling (ECC) while the basic disease mechanism remains untreated.

Download DelveInsight’s Hypertrophic Cardiomyopathy Market report today and stay ahead in this rapidly evolving field. @ Hypertrophic Cardiomyopathy Clinical Trials and advancements

Scope of the Hypertrophic Cardiomyopathy Market Report

Coverage- 7MM
Key Hypertrophic Cardiomyopathy Companies: Edgewise Therapeutics, Inc., Lexicon Pharmaceuticals, Shandong Suncadia Medicine, Ji Xing Pharmaceuticals, Rocket Pharmaceuticals, Bristol-Myers Squibb, Novartis, Gilead Sciences, Cytokinetics, Imbria Pharmaceuticals, MyoKardia, Inc., Cytokinetics, Tenaya Therapeutics, Novartis, and others
Key Hypertrophic Cardiomyopathy Therapies: EDG-7500, Sotagliflozin, HRS-1893, Aficamten, RP-A501, Mavacamten, MYK-224, LCZ696, Ranolazine, CK-3773274, IMB-1018972, MYK-461, TN-201, LCZ696, and others
Hypertrophic Cardiomyopathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Hypertrophic Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Hypertrophic Cardiomyopathy Market Access and Reimbursement

Download the report to understand which factors are driving Hypertrophic Cardiomyopathy Market Trends @ Hypertrophic Cardiomyopathy Market Trends

Table of Content

1 Key Insights

2 Report Introduction

3 Hypertrophic Cardiomyopathy Market Overview at a Glance

4 Epidemiology And Market Forecast Methodology

5 Executive Summary of Hypertrophic Cardiomyopathy

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Products

12 Hypertrophic Cardiomyopathy: Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Reimbursement and Market Access

17 Appendix

18 Bibliography

19 Report Methodology

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertrophic Cardiomyopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

“Focal Segmental Glomerulosclerosis (FSGS) Market”

Focal Segmental Glomerulosclerosis Companies are Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others.

(Albany, USA) DelveInsight’s “Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Focal Segmental Glomerulosclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted FSGS market size from 2020 to 2034, segmented by seven major markets. The Focal Segmental Glomerulosclerosis Market Report also covers current FSGS treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Focal Segmental Glomerulosclerosis market.

To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market Forecast

Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:

The Focal Segmental Glomerulosclerosis market size was valued approximately USD 734 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2022, the US accounted for approximately 34% of the total FSGS market, with projections indicating a significant compound annual growth rate (CAGR) during the study period.
In 2022, the EU4 countries and the UK generated an estimated USD 147 million, with this figure expected to grow at a significant CAGR. Among the European nations, France held the largest market share in 2022, followed by Germany.
According to DelveInsight’s assessments, there were roughly 55 million diagnosed prevalent cases of FSGS in the 7MM in 2022, with expectations of a rise during the forecast period.
In 2022, around 26 million individuals in the United States were diagnosed with FSGS, and this number is projected to rise at an estimated CAGR throughout the study period from 2020 to 2034.
In EU4 and the UK, Germany had the largest diagnosed prevalent population of FSGS in 2022, with approximately 5 million cases, followed by France and Italy. Conversely, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
The Focal Segmental Glomerulosclerosis epidemiology based on gender analyzed that Focal Segmental Glomerulosclerosis is more prevalent in males than females in the United States
The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Focal Segmental Glomerulosclerosis pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.

Focal Segmental Glomerulosclerosis Overview

Focal Segmental Glomerulosclerosis (FSGS) is a progressive kidney disease characterized by scarring (sclerosis) in segments of some glomeruli, the filtering units of the kidney. It is a leading cause of nephrotic syndrome and can result in chronic kidney disease (CKD) or end-stage renal disease (ESRD). FSGS can be classified as primary (idiopathic) or secondary, with causes including genetic mutations, infections, drug toxicity, obesity, and adaptive responses to kidney injury.

Patients with FSGS often present with proteinuria, edema, hypertension, and declining kidney function. Diagnosis is confirmed through kidney biopsy, which shows segmental sclerosis in affected glomeruli. Additional tests, including serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria levels, help assess disease severity.

Focal Segmental Glomerulosclerosis Treatment aims to reduce proteinuria, control blood pressure, and slow disease progression. Corticosteroids and immunosuppressants are first-line therapies for primary FSGS, while secondary FSGS is managed by addressing the underlying cause. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) help reduce proteinuria and protect kidney function. In severe cases, dialysis or kidney transplantation may be required.

Early Focal Segmental Glomerulosclerosis diagnosis and tailored treatment are crucial for improving outcomes and delaying kidney function decline in FSGS patients.

Get a Free sample for the Focal Segmental Glomerulosclerosis Market Report: Focal Segmental Glomerulosclerosis Market Size

Focal Segmental Glomerulosclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Focal Segmental Glomerulosclerosis Epidemiology Segmentation:

The Focal Segmental Glomerulosclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Focal Segmental Glomerulosclerosis
Prevalent Cases of Focal Segmental Glomerulosclerosis by severity
Gender-specific Prevalence of Focal Segmental Glomerulosclerosis
Diagnosed Cases of Episodic and Chronic Focal Segmental Glomerulosclerosis

Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis epidemiology trends @ Focal Segmental Glomerulosclerosis Epidemiology Forecast

Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Focal Segmental Glomerulosclerosis Therapies and Key Companies

Sparsentan: Travere Therapeutics
DMX-200: Dimerix
GFB-887: Goldfinch Bio
VX-147: Vertex Pharmaceuticals
Losmapimod: GlaxoSmithKline
Propagermanium: Dimerix Bioscience Pty Ltd
RE-021 (Sparsentan): Travere Therapeutics, Inc.
CCX140-B: ChemoCentryx
Dapagliflozin: AstraZeneca
rituximab: Genentech, Inc.
fresolimumab: Sanofi
Acthar Gel: Mallinckrodt ARD LLC
VB119: ACELYRIN Inc.
Bleselumab: Kyowa Kirin Co., Ltd.
Abatacept: Bristol-Myers Squibb

Request for sample report @ Focal Segmental Glomerulosclerosis Drugs Market

Focal Segmental Glomerulosclerosis Market Strengths

The frequency of Focal Segmental Glomerulosclerosis appears to be increasing worldwide, which presents a promising opportunity for various companies to develop novel therapies

The advent of next-generation sequencing promises to provide nephrologists with rapid and novel approaches for diagnosing and treating Focal Segmental Glomerulosclerosis

A stratified and targeted approach is being evolved based on the underlying molecular defects

Focal Segmental Glomerulosclerosis Market Unmet Needs

Heterogeneity in the disease presentation
The requirement for cutting-edge diagnosis
Restricted specific epidemiological studies
Inadequate therapeutic options

Scope of the Focal Segmental Glomerulosclerosis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Focal Segmental Glomerulosclerosis Unmet Needs, KOL’s views, Analyst’s views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement

To know more about Focal Segmental Glomerulosclerosis companies working in the treatment market, visit @ Focal Segmental Glomerulosclerosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Focal Segmental Glomerulosclerosis Market Report Introduction

2. Executive Summary for Focal Segmental Glomerulosclerosis

3. SWOT analysis of Focal Segmental Glomerulosclerosis

4. Focal Segmental Glomerulosclerosis Patient Share (%) Overview at a Glance

5. Focal Segmental Glomerulosclerosis Market Overview at a Glance

6. Focal Segmental Glomerulosclerosis Disease Background and Overview

7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Focal Segmental Glomerulosclerosis

9. Focal Segmental Glomerulosclerosis Current Treatment and Medical Practices

10. Focal Segmental Glomerulosclerosis Unmet Needs

11. Focal Segmental Glomerulosclerosis Emerging Therapies

12. Focal Segmental Glomerulosclerosis Market Outlook

13. Country-Wise Focal Segmental Glomerulosclerosis Market Analysis (2020–2034)

14. Focal Segmental Glomerulosclerosis Market Access and Reimbursement of Therapies

15. Focal Segmental Glomerulosclerosis Market Drivers

16. Focal Segmental Glomerulosclerosis Market Barriers

17. Focal Segmental Glomerulosclerosis Appendix

18. Focal Segmental Glomerulosclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Focal Segmental Glomerulosclerosis (FSGS) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

Lupus Nephritis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight

“Lupus Nephritis Treatment Market”

Lupus Nephritis companies are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.

(Albany, USA) DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Lupus Nephritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lupus Nephritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Lupus Nephritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Lupus Nephritis market.

Request for a Free Sample Report @ Lupus Nephritis Market Forecast

Some facts of the Lupus Nephritis Market Report are:

According to DelveInsight, Lupus Nephritis market size is expected to grow at a decent CAGR by 2034.
The total lupus nephritis market size in the 7MM is approximately USD 1,120 million in 2022 and is projected to increase during the forecast period (2023–2034).
In the total market size of Lupus Nephritis in the 7MM, the United States accounted for the highest market share that is more than 80% in 2023, followed by Japan and the Spain.
Leading Lupus Nephritis companies working in the market are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.
Key Lupus Nephritis Therapies expected to launch in the market are BENLYSTA (belimumab), LUPKYNIS (voclosporin), Ianalumab (VAY736), SAPHNELO (anifrolumab), GAZYVA/GAZYVARO (obinutuzumab), Anifrolumab and others.
In February 2025, the FDA cleared Allogene Therapeutics’ investigational new drug (IND) application for ALLO-329, an allogenic CAR-T cell therapy. Researchers are set to begin the Phase 1 RESOLUTION trial in mid-2025 for autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies, and systemic sclerosis.
In November 2024, Adicet Bio announced that the first LN patient had been dosed in the Phase I clinical trial evaluating ADI-001 in autoimmune diseases.
In November 2024, Kyverna Therapeutics announced that it would present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient treatments.
In October 2024, Kezar Life Sciences suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis.
In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with the first patient in screening. The company also announced the clearance by the U.S. Food and Drug Administration (FDA) of its second Investigational New Drug (IND) application for NKX019 in autoimmune disease.
In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.
In April 2024, Caribou Biosciences announced that it had received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024.
In March 2024, Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).

Lupus Nephritis Overview

Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects multiple organs. It occurs when the immune system attacks the kidneys, causing inflammation and damage to the glomeruli, leading to impaired kidney function. LN is a major cause of morbidity in lupus patients and can progress to chronic kidney disease (CKD) or end-stage renal disease (ESRD) if untreated.

Symptoms of lupus nephritis vary but commonly include proteinuria, hematuria, edema (especially in the legs and face), hypertension, and declining kidney function. Diagnosis is confirmed through kidney biopsy, which helps classify LN into different histological classes based on severity. Blood tests, urine analysis, and estimated glomerular filtration rate (eGFR) are also essential for disease monitoring.

Lupus nephritis Treatment focuses on reducing inflammation, preserving kidney function, and preventing flare-ups. Immunosuppressive therapy with corticosteroids, mycophenolate mofetil (MMF), or cyclophosphamide is the standard approach. In refractory cases, biologics like belimumab or rituximab may be used. Blood pressure control with ACE inhibitors or angiotensin receptor blockers (ARBs) is crucial in managing proteinuria.

Early Lupus nephritis diagnosis and aggressive treatment are essential to improving prognosis and preventing kidney failure in lupus nephritis patients.

Learn more about Lupus Nephritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Lupus Nephritis Treatment Market

Lupus Nephritis Market

The Lupus Nephritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Lupus Nephritis market trends by analyzing the impact of current Lupus Nephritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Lupus Nephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Lupus Nephritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Lupus Nephritis market in 7MM is expected to witness a major change in the study period 2020-2034.

Lupus Nephritis Epidemiology

The Lupus Nephritis epidemiology section provides insights into the historical and current Lupus Nephritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Lupus Nephritis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Lupus Nephritis Epidemiology @ Lupus Nephritis Market Dynamics

Lupus Nephritis Drugs Uptake

This section focuses on the uptake rate of the potential Lupus Nephritis drugs recently launched in the Lupus Nephritis market or expected to be launched in 2020-2034. The analysis covers the Lupus Nephritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Lupus Nephritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Lupus Nephritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lupus Nephritis Pipeline Development Activities

The Lupus Nephritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lupus Nephritis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Lupus Nephritis pipeline development activities @ Lupus Nephritis Drugs Market

Lupus Nephritis Therapeutics Assessment

Major key companies are working proactively in the Lupus Nephritis Therapeutics market to develop novel therapies which will drive the Lupus Nephritis treatment markets in the upcoming years are Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Otsuka Pharmaceutical, MorphoSys, Vertice Pharma, Pharmaceutical Associates Inc., Sun Pharmaceutical, Abbott, Johnson & Johnson Private Limited, Bayer, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla, and Nimble Pharmaceuticals, and others.

Learn more about the emerging Lupus Nephritis therapies & key companies @ Lupus Nephritis Clinical Trials and Advancements

Lupus Nephritis Report Key Insights

1. Lupus Nephritis Patient Population

2. Lupus Nephritis Market Size and Trends

3. Key Cross Competition in the Lupus Nephritis Market

4. Lupus Nephritis Market Dynamics (Key Drivers and Barriers)

5. Lupus Nephritis Market Opportunities

6. Lupus Nephritis Therapeutic Approaches

7. Lupus Nephritis Pipeline Analysis

8. Lupus Nephritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Lupus Nephritis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Lupus Nephritis Competitive Intelligence Analysis

4. Lupus Nephritis Market Overview at a Glance

5. Lupus Nephritis Disease Background and Overview

6. Lupus Nephritis Patient Journey

7. Lupus Nephritis Epidemiology and Patient Population

8. Lupus Nephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Lupus Nephritis Unmet Needs

10. Key Endpoints of Lupus Nephritis Treatment

11. Lupus Nephritis Marketed Products

12. Lupus Nephritis Emerging Therapies

13. Lupus Nephritis Seven Major Market Analysis

14. Attribute Analysis

15. Lupus Nephritis Market Outlook (7 major markets)

16. Lupus Nephritis Access and Reimbursement Overview

17. KOL Views on the Lupus Nephritis Market

18. Lupus Nephritis Market Drivers

19. Lupus Nephritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lupus Nephritis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, MOA, ROA, and Companies by DelveInsight

Gastrointestinal Stromal Tumor (GIST) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

“Gastrointestinal Stromal Tumor (GIST) Market”

Gastrointestinal Stromal Tumor Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

(Albany, USA) DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Gastrointestinal Stromal Tumor market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gastrointestinal Stromal Tumor market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atopic Dermatitis market.

Discover Key Insights into the Gastrointestinal Stromal Tumor Market with DelveInsight’s In-Depth Report @ Gastrointestinal Stromal Tumor Market Size

Key Takeaways from Gastrointestinal Stromal Tumor Market Report

The GIST therapeutic market in the 7MM was around USD 450 million in 2023.

In December 2024:- Deciphera Pharmaceuticals- The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
In December 2024:- Cogent Biosciences Inc.- This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs.
In the assessment done by DelveInsight, the estimated total incident cases of GIST in the 7MM were nearly 16 thousand in 2023.
The highest incident cases of GIST were accounted by the US in 2023 (approximately 7k cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 43% of the total cases in the 7MM.
In 2023, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with nearly 6 thousand cases in the 7MM, followed by age group 51-65 years with around 5 thousand cases. While the least number of cases were seen in the age group 0-17 years.
Among the European countries, Germany had the highest incident population of GIST with nearly 2 thousand cases, followed by Italy, which had incident population of over 1k in 2023. On the other hand, Spain had the lowest incident population.
Japan had more than 2,500 incident cases for GIST in 2023, accounting for approximately 16% of total incident cases in the 7MM.
In 2023, our estimations indicate that within the 7MM, a higher percentage of males (52%) were affected by Gastrointestinal Stromal Tumor (GIST) compared to females (48%). The reason for this gender difference could be attributed to various factors, including potential differences in genetic susceptibility, hormonal influences, occupational exposures, lifestyle habits, and healthcare-seeking behaviors.
The leading Gastrointestinal Stromal Tumor Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
Promising Gastrointestinal Stromal Tumor Therapies such as TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others

Stay ahead in the Gastrointestinal Stromal Tumor Therapeutics Market with DelveInsight’s Strategic Report @ Gastrointestinal Stromal Tumor Market Outlook

Gastrointestinal Stromal Tumor Epidemiology Segmentation in the 7MM

Total Prevalence of Gastrointestinal Stromal Tumor
Prevalent Cases of Gastrointestinal Stromal Tumor by severity
Gender-specific Prevalence of Gastrointestinal Stromal Tumor
Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Prevalence

Gastrointestinal Stromal Tumor Marketed Therapies

Ayvakit (Avapritinib): Blueprint Medicines Corporation

Ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations and Advanced Systemic Mastocytosis (AdvSM). The FDA granted full approval to Ayvakit based on efficacy results from the Phase I NAVIGATOR clinical trial, as well as combined safety results from multiple clinical trials for avapritinib.

STIVARGA (Regorafenib): Bayer

Stivarga (BAY 73-4506) is the brand name for the generic chemotherapy agent regorafenib, an oral anticancer medication approved by the FDA for individuals with locally advanced, unresectable, or metastatic GIST who have previously received imatinib mesylate and sunitinib malate. In September 2021, Bayer presented study results indicating close proximity to the prespecified activity threshold, possibly influenced by a low recruitment rate. The notable frequency of undetected mutant GIST by Sanger sequencing underscores the importance of next-generation sequencing (NGS) in presumed KIT/PDGFR wild-type GIST.

Gastrointestinal Stromal Tumor Emerging Therapies

Crenolanib: Arog Pharmaceuticals

Crenolanib, an investigational small molecule drug, is currently undergoing Phase III clinical trials to assess its safety and efficacy in treating acute myeloid leukemia (AML) and gastrointestinal stromal tumor (GIST). Acting as a potent inhibitor of both wild-type and mutant forms of FLT3 (FMS-like Tyrosine Kinase 3) and PDGFRα/β (Platelet-derived Growth Factor Receptor), Crenolanib holds promise as a potential additional treatment option for patients with advanced or metastatic GIST harboring a D842V mutation in the PDGFRA gene, offering hope for improved outcomes in this specific subgroup.

Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.

Bezuclastinib (CGT9486) is a highly selective Type I inhibitor of KIT receptor tyrosine kinase, specifically targeting oncogenic KIT with mutations in the activation loop encoded by exons 17 and 18, including the pivotal KIT D816V mutation found in the majority of patients with systemic mastocytosis. The combination of bezuclastinib with sunitinib, a Type-II inhibitor effective against KIT ATP-binding pocket mutations, demonstrated prolonged progression-free survival in extensively treated patients with gastrointestinal stromal tumor. Cogent Biosciences, Inc. holds worldwide rights to bezuclastinib, encompassing all facets of development, manufacturing, and commercialization activities related to this promising molecule.

Get In-Depth Knowledge on Gastrointestinal Stromal Tumor Market Trends and Forecasts with DelveInsight @ Gastrointestinal Stromal Tumor Treatment Market

Gastrointestinal Stromal Tumor Market Outlook

Knowledge about the underlying genetic alterations revealed possible targeted treatment with TKIs such as imatinib and sunitinib. Continuous research efforts helped to further elucidate molecular insights of this disease and allowed the development of new treatment options based on the underlying molecular signature. Currently, there are seven therapies approved for GIST that includes five TKIs, and two NTRK inhibitors such as GLEEVEC (Imatinib Mesylate), STIVARGA (Regorafenib), SUTENT (sunitinib malate), AYVAKIT (avapritinib), QINLOCK (Ripretinib), ROZLYTREK (Entrectinib), and VITRAKVI (Larotrectinib), approved in different lines. Along with these, there are certain therapies being used as off-label therapies in patients resistant to approved therapies.

Gastrointestinal Stromal Tumor Treatment Market Landscape

In the landscape of advanced GIST treatment, GLEEVEC (imatinib mesylate) stands as the approved first-line therapy, followed by SUTENT (sunitinib) as a second-line option for those resistant or intolerant to imatinib. In real-world scenarios, SUTENT or regorafenib may even be considered as first-line therapies in cases of intolerance or severe adverse events with imatinib. STIVARGA (regorafenib) and QINLOCK (ripretinib) are approved as third and fourth-line options, respectively. Notably, emerging therapies such as Crenolanib, Bezuclastinib, and others are being investigated for GIST and are anticipated to get approved during the forecast period (2024–2034).

Unlock Strategic Insights with DelveInsight’s Comprehensive Gastrointestinal Stromal Tumor Market Report @ Gastrointestinal Stromal Tumor Market Drivers and Barriers

Scope of the Gastrointestinal Stromal Tumor Market Report

Study Period: 2020–2034
Coverage: 7MM
Key Gastrointestinal Stromal Tumor Companies: Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics and others
Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers

Table of Contents

1. Gastrointestinal Stromal Tumor Market Report Introduction

2. Executive Summary for Gastrointestinal Stromal Tumor

3. SWOT analysis of Gastrointestinal Stromal Tumor

4. Gastrointestinal Stromal Tumor Patient Share (%) Overview at a Glance

5. Gastrointestinal Stromal Tumor Market Overview at a Glance

6. Gastrointestinal Stromal Tumor Disease Background and Overview

7. Gastrointestinal Stromal Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastrointestinal Stromal Tumor

9. Gastrointestinal Stromal Tumor Current Treatment and Medical Practices

10. Gastrointestinal Stromal Tumor Unmet Needs

11. Gastrointestinal Stromal Tumor Emerging Therapies

12. Gastrointestinal Stromal Tumor Market Outlook

13. Country-Wise Gastrointestinal Stromal Tumor Market Analysis (2020–2034)

14. Gastrointestinal Stromal Tumor Market Access and Reimbursement of Therapies

15. Gastrointestinal Stromal Tumor Market Drivers

16. Gastrointestinal Stromal Tumor Market Barriers

17. Gastrointestinal Stromal Tumor Appendix

18. Gastrointestinal Stromal Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastrointestinal Stromal Tumor (GIST) Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

MASH Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

“MASH Treatment Market”

MASH companies are Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene, Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others.

(Albany, USA) DelveInsight’s Metabolic Dysfunction-Associated Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, MASH emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report

The total MASH market size in the 7MM was approximately USD 2,114 million in 2023 and is projected to increase during the forecast period (2024–2034).

In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM.
Leading MASH companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others are developing novel MASH drugs that can be available in the MASH market in the coming years.
The promising MASH therapies in the pipeline include Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others.
In March 2024, Madrigal Pharmaceuticals’ groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-ß agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2–F3 fibrosis.

Discover which therapies are expected to grab the major MASH market share @ Metabolic Dysfunction-Associated Steatohepatitis Market Report

Metabolic Dysfunction-Associated Steatohepatitis Overview

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from metabolic dysfunction, often linked to obesity, diabetes, and other conditions of metabolic syndrome. MASH is characterized by the accumulation of fat in liver cells, accompanied by inflammation and liver cell injury, which can progress to fibrosis, cirrhosis, or even liver cancer.

The primary drivers of MASH include insulin resistance, obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and a sedentary lifestyle also play significant roles. Environmental factors, such as a poor diet high in sugars and fats, exacerbate the condition.

MASH is often asymptomatic in its early stages. When MASH symptoms occur, they can include fatigue, vague abdominal discomfort, or pain in the upper right quadrant. In advanced stages, signs of liver dysfunction such as jaundice, swelling of the abdomen or legs, and confusion may arise.

MASH Diagnosis involves a combination of clinical history, physical examination, and diagnostic tests. Blood tests measuring liver enzymes (ALT, AST) often indicate liver inflammation. Imaging techniques like ultrasound, MRI, or FibroScan can identify liver fat and fibrosis. In some cases, a liver biopsy is required to confirm the diagnosis and assess disease severity.

Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation

The MASH epidemiology section provides insights into the historical and current MASH patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The MASH market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Prevalent Cases of MASH
Diagnosed Prevalent Cases of MASH
Gender-specific Diagnosed Prevalent Cases of MASH
Severity-specific Diagnosed Prevalent Cases of MASH

MASH Treatment Market

The approval of REZDIFFRA (resmetirom) in March 2024 represents a pivotal achievement in medical innovation, transforming the treatment landscape for MASH disease. This groundbreaking therapy addresses the root causes of MASH, offering renewed hope to patients grappling with this challenging condition. Clinical trials have shown impressive results, with REZDIFFRA effectively reducing symptoms like inflammation and fibrosis, enhancing liver function, and improving patients’ quality of life. By providing healthcare professionals with a robust treatment option, this approval addresses a critical unmet need and has the potential to significantly alleviate the complications linked to advanced liver disease.

The prevalence of MASLD is strongly linked to type 2 diabetes mellitus and obesity, particularly in individuals with a higher body mass index. However, MASLD occurrence is reduced in T2DM patients receiving treatments such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, GLP-1 receptor agonists, and insulin. Vitamin E, with its antioxidant properties, is regarded as a first-line pharmacological option for managing MASH, especially when dietary and lifestyle interventions are insufficient.

To know more about MASH treatment guidelines, visit @ Metabolic Dysfunction-Associated Steatohepatitis Management

Metabolic Dysfunction-Associated Steatohepatitis Pipeline Therapies and Key Companies

Lanifibranor (IVA337): Inventiva Pharma
Semaglutide: Novo Nordisk A/S
Azemiglitazone (MSDC-0602K): Cirius Therapeutics
Efruxifermin (EFX): Akero Therapeutics
BIO89-100 (Pegozafermin): 89bio
Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
GR-MD-02 (Belapectin): Galectin Therapeutics
LPCN1144: Lipocine
VK2809: Viking Therapeutics
Tirzepatide: Eli Lilly and Company
BOS-580: Boston Pharmaceuticals
Ervogastat (PF-06865571) + Clesacostat (PF-05221304): Pfizer
HTD1801: HighTide Biopharma
Leronlimab (PRO 140): CytoDyn
Efinopegdutide: Merck & Co./Hanmi Pharmaceutical
HPG1860: Hepagene (Shanghai)
Rencofilstat (CRV431): Hepion Pharmaceuticals
EYP001 (Vonafexor): Enyo Pharmaceuticals
Semaglutide/ Cilofexor/ Firsocostat: Gilead Sciences
PXL065: Poxel SA
Saroglitazar Magnesium: Zydus Therapeutics
Denifanstat (TVB-2640): Sagimet Biosciences
ION224: Ionis Pharmaceuticals
Miricorilant (CORT118335): Corcept Therapeutics

Discover more about MASH drugs in development @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials and Advancements

MASH Market Dynamics

The MASH market dynamics are expected to change in the coming years. Growing research activities and multiple clinical trials for MASH, driven by the rapid surge in its prevalence due to rising obesity and type 2 diabetes rates, highlight an active drug development pipeline and an expanding market size. The large pool of patients and lucrative growth opportunities present attractive prospects for key players, further supported by ongoing preclinical studies aimed at advancing imaging techniques for MASH diagnosis, potentially eliminating the need for invasive biopsy-based histopathological confirmation.

Furthermore, potential therapies are being investigated for the treatment of MASH, and it is safe to predict that the treatment space will significantly impact the MASH market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the MASH market in the 7MM.

However, several factors may impede the growth of the MASH market. Lack of awareness and negligence in the early stages of MASH by physicians often lead to disease progression, culminating in irreversible damage where liver transplantation becomes the only viable option. Diagnosing advanced MASH typically requires procedures like liver biopsy, which are costly, invasive, and risky. Regulatory challenges also pose hurdles, as the FDA mandates achieving one MASH endpoint for approval, while the EMA’s draft guidance requires efficacy in both endpoints, potentially delaying first-mover approvals in major European markets. Additionally, access to expensive MASH treatments may be limited in certain regions, further hindering patient adoption.

Moreover, MASH treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, MASH market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact MASH market growth.

Download the report to understand which factors are driving MASH drugs and therapies in pipeline @ Metabolic Dysfunction-Associated Steatohepatitis Treatment Market

Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report

Study Period: 2020–2034
Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Metabolic Dysfunction-Associated Steatohepatitis CAGR: 17.9 %
Metabolic Dysfunction-Associated Steatohepatitis Market Size in 2023: USD 2.1 Billion
Key Metabolic Dysfunction-Associated Steatohepatitis Companies: Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others
Key Pipeline Metabolic Dysfunction-Associated Steatohepatitis Therapies: Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others
Therapeutic Assessment: Metabolic Dysfunction-Associated Steatohepatitis current marketed and emerging therapies
Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics: Key Market Forecast Assumptions of Emerging Metabolic Dysfunction-Associated Steatohepatitis Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement

Download the report to understand which factors are driving MASH market trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends

Table of Contents

1. Key Insights

2. Report Introduction

3. Country-wise MASH Market Overview at a Glance

4. MASH Market Overview by Therapeutic Class

5. Methodology of MASH Epidemiology and Market

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. MASH Epidemiology and Patient Population

10. MASH Patient Journey

11. Marketed MASH Drugs

12. Emerging MASH Drugs

13. MASH Market Analysis

14. Key Opinion Leaders’ Views

15. SWOT Analysis

16. Unmet needs

17. Market Access and Reimbursement

18. Appendix

19. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: MASH Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA and Companies by DelveInsight

Scott L Gordon Reveals the Blueprint for Real Estate Wealth in His New Book: “Making Millions Investing in Rental Properties”

“By Scott L Gordon”

Financial independence is no longer a distant dream. In his groundbreaking new book, Making Millions Investing in Rental Properties: Unlocking Real Estate Wealth – My Journey to Multimillion-Dollar Success, seasoned real estate investor and entrepreneur Scott Gordon unveils a proven roadmap to building lasting wealth. Combining decades of real-world experience with actionable insights, Gordon empowers readers to take control of their financial futures through the transformative power of real estate investing.

Scott Gordon’s journey is one of perseverance, vision, and impact. Frustrated by the uncertainties of traditional investments, he turned to real estate as a pathway to financial freedom. Over time, through strategic planning and persistence, Gordon built a multimillion-dollar portfolio of rental properties. In this book, he shares the lessons learned along the way — lessons that anyone, regardless of experience, can apply to achieve success.

This book goes beyond theory to provide practical, step-by-step guidance for every stage of the real estate investment journey. Whether you’re a beginner exploring your first property purchase or an experienced investor looking to scale, Making Millions offers something for everyone. Highlights include:

• Step-by-Step Strategies: Master the essentials of property acquisition, financing, and leveraging equity.

• Real-Life Lessons: Learn from Gordon’s challenges and triumphs, with practical tips to avoid common pitfalls.

• Advanced Techniques: Explore strategies like 1031 exchanges, scaling portfolios, and diversifying investments.

• Community-Centered Investing: Understand the importance of tenant relationships and creating resilient communities.

Scott Gordon emphasizes that real estate investing isn’t just for the wealthy or elite. With the right mindset, discipline, and knowledge, anyone can unlock financial independence. His message is clear: Real estate can change lives — not just for investors, but for the communities they serve.

Scott Gordon is a successful real estate investor, entrepreneur, and pastor with decades of experience in ministry and community service. From rebuilding homes in low-income areas to serving as a missionary across the globe, Gordon has dedicated his life to creating opportunities for others. Now, he’s sharing his expertise to inspire and equip others to achieve financial freedom through real estate.

Making Millions Investing in Rental Properties: Unlocking Real Estate Wealth – My Journey to Multimillion-Dollar Success is available now in print and digital formats. Find it on Amazon, Barnes & Noble, and other major retailers.

Take the first step toward building your financial legacy — get your copy today!

Amazon https://a.co/d/2OBwiTy

Media Contact
Company Name: Book Writing Genie
Contact Person: Scott L Gordon
Email: Send Email
City: Tulsa
State: Oklahoma
Country: United States
Website: https://bookwritinggenie.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Scott L Gordon Reveals the Blueprint for Real Estate Wealth in His New Book: “Making Millions Investing in Rental Properties”

“Immortal Thoughts: 333 Word Power” – It’s All About Love, Faith, and the Human Experience

“by JEVARNE BECKFORD”

Jevarne Beckford’s latest book is a quiet yet powerful exploration of life’s big questions, wrapped in 333 bite-sized reflections.

There’s something about Immortal Thoughts: 333 Word Power that feels like sitting down with an old friend who knows just what to say. Jevarne Beckford’s new book isn’t here to shout or sell; it’s here to sit with you, to make you think, and maybe even to make you feel a little less alone.

It’s a collection of 333 thoughts—some poetic, some philosophical, all deeply human. Divided into five chapters, the book moves through love, faith, motivation, philosophy, and spirituality, offering moments of clarity and connection along the way.

It’s not a self-help book. It’s not a guide. It’s more like a conversation—one that doesn’t pretend to have all the answers but is willing to ask the right questions. Beckford’s words feel personal, as if they were written just for you, even though they speak to something universal.

For example, in the chapter on Love and Relationships, there’s this line: “Love is heavy. I know this because it made me weak in the knees, and I ended up falling for you.” It’s simple, but it hits hard. It’s the kind of line that makes you pause and think about your own experiences with love—its weight, its beauty, its messiness.

Then there’s the chapter on Faith and Divinity, where Beckford writes, “Faith is your mind’s ability to reserve a seat at opportunity’s table, even when you were not invited.” It’s a reminder that faith isn’t just about belief; it’s about hope, persistence, and the quiet courage to keep going.

What stands out about Immortal Thoughts is how it balances the profound with the everyday. It’s not trying to be grand or overly intellectual. Instead, it feels grounded, like the kind of wisdom you’d share over a cup of coffee or during a late-night conversation.

Take this line from the chapter on Motivation and Self-Actualization: “Fear is an inconsiderate thief which takes away the best of your courage.” It’s a small sentence, but it carries a big truth—one that might just nudge you to face something you’ve been avoiding.

Or this one, from Philosophy and Society: “A good reputation is like virginity. When it’s gone, you can never get it back.” It’s sharp, a little playful, but it makes you think about the weight of our choices and how they shape the way others see us.

Anyone who’s ever felt stuck, lost, or just curious about life. Anyone who’s ever wondered why love feels so complicated, why faith can be so hard to hold onto, or why music has the power to move us so deeply. It’s for thinkers, dreamers, and anyone who appreciates the beauty of a well-turned phrase.

Jevarne Beckford has a way with words that feels both intimate and expansive. This book is a testament to Beckford’s ability to capture the essence of what it means to be human—our struggles, our joys, and the quiet moments in between.

Immortal Thoughts: 333 Word Power is available now at bookstores and online. It’s the kind of book you’ll want to keep on your nightstand, flipping through whenever you need a little insight or inspiration.

Amazon https://a.co/d/1fx1Twm

Media Contact
Company Name: Hemingway Publishers
Contact Person: JEVARNE BECKFORD
Email: Send Email
City: New York
State: New York
Country: United States
Website: https://hemingwaypublishers.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: “Immortal Thoughts: 333 Word Power” – It’s All About Love, Faith, and the Human Experience

Pam Gittleman’s Nursery Rhymes for Kinder Times® Volume 2 Offers A Modern Twist On Traditional Nursery Rhymes, Fostering Social and Emotional Growth in Young Readers

Featuring relatable, uplifting takes on traditional rhymes, Nursery Rhymes for Kinder Times® Volume 2 by Pam Gittleman offers nine new updated nursery rhymes that are less dark and outdated than their original versions, with new storylines that nurture kindness, empathy, and gratitude. Scheduled for retail release in March 2025, this engaging collection supports social and emotional learning in preschoolers, making it a joy for families and educators to share.

Pam Gittleman is a Multi-Award-Winning Author, Early Childhood Music Educator, and the Creator of Nursery Rhymes for Kinder Times®.

As an early childhood music educator for over 25 years, Pam has a strong passion for singing, rhyming, reading stories, and making music with preschoolers. She created Nursery Rhymes for Kinder Times®, a collection of updated nursery rhymes that are more relevant and kind than their predecessors, to empower families and educators with research-based tools to nurture social-emotional learning (SEL) and foster positive values in young children.

Pam’s journey began with the release of the Nursery Rhymes for Kinder Times album, a collaboration with world-renowned children’s artists Raffi and Lindsay Munroe. Building on its success, she expanded into videos and books, creating engaging multimedia experiences for young learners. She then collaborated with the “Queen of Children’s Music”, Laurie Berkner, to release an EP of three additional rhymes. With millions of song streams, a growing YouTube channel, and numerous literary awards, Pam’s work continues to resonate with families and educators alike.

A former VP at Ogilvy and Mather Advertising with an MBA from Wharton, Pam transitioned to music education to pursue her passion for early childhood development. She later deepened her expertise at Harvard’s Advanced Leadership Initiative, where she refined her mission to create equitable, accessible resources for all children. Aside from making music with kids, Pam loves dogs and dark chocolate. She lives in New York with her husband and cherishes time spent with her children, grandchildren and granddogs.

This one-on-one interview shares Pam’s background and experience writing Nursery Rhymes for Kinder Times®, Volume 2.

Tell us about Nursery Rhymes for Kinder Times®, Volume 2.

Nursery Rhymes for Kinder Times®, Volume 2 contains nine updated nursery rhymes that foster kindness, empathy, and gratitude.

From This Little Piggy (where a pig family is sharing food at a picnic and no pigs are going to market!) to Rock-a-Bye Baby (where a kind brother and sister are soothing a baby owl in a swinging cradle that does NOT fall out of the tree), all nine rhymes include relevant and kind stories that parents and teachers can feel good about reading (or singing!) together.

The nine rhymes in this book are: This Little Piggy, Rock-a-Bye Baby, Peter Peter Pickle Eater, Old Mother Hubbard, Diddle Diddle Dumpling, Rub a Dub Dub, Sing a Song of Six Cents, There Was a Nice Lady, Tom Tom the Plumber’s Son.

Each rhyme is accompanied by research-based tools for parents and teachers that support social and emotional learning and language development. From QR codes to hear each rhyme read aloud, discussion questions to stimulate conversations, and emojis to support emotional development, everyone can feel good about sharing these new rhymes with the young children they love.

Nursery Rhymes for Kinder Times® is a multimedia brand. Why is it important to incorporate music and video content in regards to early childhood education?

Music has been shown to support cognition, language learning (phonological awareness, vocabulary, comprehension) and social and emotional well-being.

The music came before the books as a result of acclaimed children’s music artist, Raffi, taking an interest in our concept. He loved the updated rhymes and produced music for 15 of them in the Nursery Rhymes for Kinder Times album released in May 2022.

Afterwards I wanted to add visuals that would illustrate the characters in the rhymes in a variety of social situations and experiencing a variety of emotions that young kids could relate to. So, we created videos that included a diverse array of characters, situations and emotions to accompany the recorded music.

While the music and videos provided different modalities to support early childhood skill development, the books added a new level of engagement by supporting young learners on their literacy journeys. With the books, they could go from listening to the rhymes being read by others while looking at the illustrations, to talking about the characters and stories, to eventually learning to read the rhymes on their own. In addition, both the books and the videos gave us an opportunity to include tools, in the form of guiding questions and emojis, to support social and emotional learning, which is critical to early childhood development, long-term academic success, and has become an important part of our brand identity.

With all the success of the Nursery Rhymes for Kinder Times® brand, what are your plans for the future?

I’m thrilled that our 18 recorded rhymes, performed by iconic artists like Raffi, Lindsay Munroe, and Laurie Berkner, have surpassed 10 million song streams!

With a growing YouTube channel featuring videos for all our rhymes and the completion of Nursery Rhymes for Kinder Times® Volumes 1 and 2, I’m already envisioning the possibilities for Volume 3.

I’m eager to collaborate with more incredible artists and continue creating music, videos, and stories that inspire joy, kindness, and connection among young learners everywhere!

Purchasing the Book

Nursery Rhymes for Kinder Times® Volume 2 is available for pre-order on Amazon, Barnes & Noble and Walmart. The book’s retail release is scheduled for March 2025, but a special bundle discount of Volume 1 and 2 is currently available now and can be purchased directly from Pam’s publisher, Mascot Books: Nursery Rhymes for Kinder Times® Volume 1 & 2 Bundle.

To celebrate the book’s release, Pam will be attending family and early childhood education events and the book will be part of a virtual book tour starting in March.

To connect with Pam, visit www.pamgittleman.com, Facebook (@ForKinderTimes) and Instagram (@forkindertimes). To hear recorded songs of all the rhymes, as well as low-stimulation videos that bring each rhyme to life, visit: www.youtube.com/@nurseryrhymesforkindertimes.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pam Gittleman’s Nursery Rhymes for Kinder Times® Volume 2 Offers A Modern Twist On Traditional Nursery Rhymes, Fostering Social and Emotional Growth in Young Readers

How Gratitude Saved Her Life: Miriam Smith Stevens on Turning Trauma into Triumph

Miriam Smith Stevens has developed The CPR Plus N.O.W. Framework, a powerful roadmap for overcoming adversity and reclaiming purpose.

One night changed everything for Miriam Smith Stevens. A masked intruder tightened his grip around her throat, and in that moment, she thought: “This is it. This is how I die.” But instead of giving in, she negotiated for her life—a decision that not only saved her but became the foundation for a global movement in resilience and transformation.

Video Link: https://www.youtube.com/embed/BskC_2aLYLU

Today, as the founder of The Thankful Revolution Legacy Group LLC, Stevens helps others pivot from crisis to clarity through gratitude, mindset mastery, and personal branding. She recently joined Dr. Tami Patzer on Business Innovators to share how she transformed tragedy into triumph—and how others can do the same.

“I shouldn’t be here today. But in my darkest moment, I realized: Pain is inevitable. Suffering is a choice. That’s when I decided to pivot—because I knew there had to be something greater waiting for me,” said Stevens.

From Survivor to Changemaker: The CPR Plus N.O.W. Framework Stevens developed The CPR Plus N.O.W. Framework, a powerful roadmap for overcoming adversity and reclaiming purpose:

• Crisis – The inevitable disruptions that shake us to our core. • Pivot – The decision to shift and find a new direction. • Rebirth – Emerging from adversity with a renewed sense of purpose. • Plus – The faith, values, or personal foundation that provides strength. • New Beginnings – The transformation that follows resilience.

“We all face crises, but what happens next is up to us,” said Stevens. “It’s not about avoiding hardship—it’s about pivoting through it.”

Five R’s to Thrive: The Blueprint for Personal Reinvention

In addition to CPR Plus N.O.W., Stevens introduced Five R’s to Thrive, a step-by-step system to reclaim personal power:

• Reclaim Your Voice – Speak your truth and embrace authenticity. • Resuscitate Your Passion and Purpose – Rediscover what fuels you. • Rebound from Trauma – Build resilience and move forward. • Renew Your Mindset – Shift from limitations to possibilities. • Rewrite Your Story – Take control of your narrative and future.

“The mind is a battlefield, and what we focus on determines our reality,” Stevens said.

“By choosing gratitude and embracing our journey, we can transform even the darkest moments into opportunities for growth.”

Helping Others Find Their Life Song

Beyond coaching, Stevens is known as The Brand Paramedic, specializing in personal branding, messaging, and mindset breakthroughs. One of her unique offerings is helping clients discover their life song—a personal anthem that fuels motivation.

“Music was my therapy,” Stevens shares. “When I was struggling, two songs kept me going: Just Fine by Mary J. Blige and I Speak Life by Donald Lawrence. Now, I create custom life songs for my clients to inspire them on their journey.”

Dream Discovery Dialog Discussion Sessions: Uncovering Hidden Potential

Stevens also offers Dream Discovery Dialog Discussion Sessions, personalized coaching designed to help individuals rediscover their dreams and create actionable strategies for success.

“Many people have dreams they abandoned years ago,” she said.

“These sessions are about pulling those dreams back into focus and turning them into reality.”

One of her standout clients and colleagues in the mindset transformation movement, Constance Wills, a former probation officer, felt lost after retirement. Through Stevens’ guidance, Wills launched Beauty Beyond the Wall, a movement focused on mindset transformation.

“Miriam isn’t just another motivational speaker—she’s proof that transformation is possible,” said Patzer.

“Her journey from survivor to global leader is nothing short of extraordinary. She’s not just inspiring people; she’s changing lives, one pivot at a time.” said client Constance, “I have experienced firsthand the immense value of the services offered as I listen, almost daily to the life song Ms. Miriam Smith Stevens created for me. Using her unique, innovative, and inspiring coaching style, your story of transformation will come to life, while the music created specifically for you serves as an empowering anthem, reminding you of your potential and reinforcing your vision.”

Join the Movement: Your Transformation Starts Now Your Next Pivot Starts NOW!

If you’re ready to stop feeling stuck and start thriving, visit TheThankfulRevolutionLegacyGroup.com.

You’ll find: FREE resources to reclaim your voice & purpose (Complimentary Gift Download your copy by scrolling to the bottom of the website for There is a C.U.R.E. within the O.B.S.C.U.R.E. wilderness of your life’s journey!)

Personal coaching through Dream Discovery Dialog Discussion Sessions:

A powerful community of like-minded changemakers

Your transformation starts with one decision. Are you ready? Click here: https://forms.gle/S9ZunvjY2XzphPBB6

About Business Innovators

Business Innovators, hosted by Dr. Tami Patzer, features conversations with industry leaders, entrepreneurs, and changemakers who are driving innovation and transformation in their fields. The show provides insights, strategies, and inspiration for professionals looking to elevate their impact and success.

For media inquiries, interviews, or additional information, contact:

Email: information@thethankfulrevolutionlegacygroupllc.com

Personal: miriamsmithstevens@yahoo.com

Website: thethankfulrevolutionlegacygroup.com

Media Contact
Company Name: The Thankful Revolution Legacy Group LLC
Contact Person: Miriam Smith Stevens
Email: Send Email
Phone: 757 303 6058
Country: United States
Website: thethankfulrevolutionlegacygroup.com